



ECNP Research & Scholarship
Foundation

Annual Report 2022

ECNP Research and Scholarship Foundation

Annual Report 2022

1. About ECNP R&S	3
Objectives	3
Board	3
2. Activities 2022	4
Scientific and educational meetings	4
Awards	5
Other major initiatives	5
3. Financial Overview	6
Financial statements	6
4. Future Outlook	8



The ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP R&S

The ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Address: Daltonlaan 400, 3584 BK Utrecht, The Netherlands

E-mail: secretariat@ecnp.eu

Website: <https://www.ecnp.eu>

RSIN: 807967087

Dutch Chamber of Commerce number: 41215196

Dutch TAX number: NL807967087B01

ANBI: The ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

Objectives

ECNP R&S is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Board

Martien Kas
President
The Netherlands

Brenda Penninx
Treasurer
The Netherlands

Suzanne Dickson
Secretary
Sweden

The members of the board receive no remuneration for their role.

Alexander Schubert
Executive Director
The Netherlands

2. Activities 2022

To execute its mission to support European applied and translational neuroscience, ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2022 the following programmes were delivered:

Scientific and educational meetings

- **ECNP Workshop for Early Career Scientists in Europe**
17-20 March 2022 – Nice, France
The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.
- **ECNP New Frontiers Meeting in Digital Health**
20-21 March 2022 – Nice, France
A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2022 meeting explored a range of topics, from decentralised trials, digital (mobile) endpoints, and digital therapeutics.
- **ECNP School of Child and Adolescent Neuropsychopharmacology**
27 March-1 April 2022 – Venice, Italy
The School offers European early career clinicians a focused programme of intensive training in neuropsychopharmacology for children and adolescents.
- **ECNP Seminar in Neuropsychopharmacology**
12-13 May 2022 – virtual
This high-impact training course is offered for developing-economy countries, to enhance knowledge and skills in a concentrated learning environment with local and international experts.
- **ECNP Workshop on Clinical Research Methods**
9-11 November 2022, Barcelona, Spain
The Workshop offers 50 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists.
- **ECNP Small Private Online Course (SPOC): 'Introduction to Neuropsychopharmacology'**
This online training course prepares early career clinicians for ECNP R&S educational activities, seminars, schools and internships offers modules covering neuroanatomy, neurophysiology, neurogenetics, psychopharmacology, immunology and statistics.

Awards

- **ECNP Citation Prize**

Awarded to the most-cited research paper in the ECNP journal, *European Neuropsychopharmacology* (ENP) in the preceding two years, the award recognises and encourages impactful original research. The 2022 winner was Martin Madsen et al., 'A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT_{2A} receptor binding' *Eur. Neuropsychopharmacol.* 33, 2020, 71-80.

Other major initiatives

- **Neuroscience-based Nomenclature (NbN)**

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2022 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached over 100,000 downloads worldwide, with translations in French, Spanish and Chinese, and Portuguese and patient-and-family versions in preparation.

- ***Neuroscience Applied***

This fully open-access scientific journal targets the intersection between neuroscience, applications and new treatment horizons, and features original basic, clinical and integrative research with translational relevance for mental health. Focusing especially on neuroscientific approaches to brain disorders, it encompasses mechanisms of disorders, biological, psychological and social treatments, prevention and policies. The journal is fully owned by ECNP R&S

3. Financial Overview

ECNP R&S's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Capital preservation – at the levels agreed with the Dutch tax authorities
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

The market downturn in 2022 resulted in significant losses to ECNP R&S's equity holding. Ongoing risk management and adjustment of the cost base will be a priority going forward.

Financial statements

Balance sheet as at 31 December 2022

(after appropriation of profit/losses)

	31-12-2022		31-12-2021	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		11,018,368		11,018,368
CURRENT ASSETS				
Accounts receivable				
Debtors	13,076		14,134	
Amounts owed by congress foundations	309,192		190,818	
Taxes	1,377		412	
Other accounts receivables	82,240		78,839	
		405,885		284,203
Bank deposits		2,064,730		2,162,458
		2,470,615		2,446,661
		<u>13,488,983</u>		<u>13,465,029</u>

	31-12-2022		31-12-2021	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY AND FUNDS				
Other reserves		13,432,839		13,407,009
CURRENT LIABILITIES				
Trade creditors	31,521		35,268	
Other liabilities	24,623		22,752	
		56,144		58,020
		<u>13,488,983</u>		<u>13,465,029</u>

Statement of income and expenditure 2022

	Balance 2022	Balance 2021
	€	€
Income		
Proceeds fundraising	696,078	185,641
Journal Neuroscience Applied	18,000	33,500
Neuroscience-based Nomenclature	24,407	16,932
Interest and similar income	-	103,368
Total income	<u>738,485</u>	<u>339,441</u>
Expenses		
Administration	301,137	268,528
Meetings	255,827	40,070
Journal Neuroscience Applied	29,000	11,250
Neuroscience-based Nomenclature	101,637	87,749
Other expenses	18,381	5,587
Total expenses	<u>705,982</u>	<u>413,184</u>
Balance before financial expense	<u>32,503</u>	<u>-73,743</u>
Interest and similar charges	-6,673	-8,358
Net result	<u>25,830</u>	<u>-82,101</u>
Appropriation of result		
Other reserves	<u>25,830</u>	<u>-82,101</u>

4. Future Outlook

Technological advances, the climate emergency, geopolitical instability have all combined to make the post-Covid world a very different place. As it has for organisations everywhere, the new reality has raised some fundamental questions about ECNP R&S's future role and what adaptations will have to be made to maintain its relevance and long-term economic viability. Formulating a response to these questions is the organisation's current strategic focus. Specific issues include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the College's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

Plans are being developed to effect change and renewal in all of these areas and equip the organisation with the structures and systems necessary to meet the next 35 years of its existence.

